Blood Res.  2016 Sep;51(3):200-203. 10.5045/br.2016.51.3.200.

Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study

• Joo SH
• Park JK
• Lee EE
• Song YW
• Yoon SS

• KMID: 2353502
• DOI: http://doi.org/10.5045/br.2016.51.3.200

Abstract

BACKGROUND
Since cell turnover in the hematopoietic system constitutes a major source of uric acid (UA) production, we investigated whether hematopoietic stem cell transplantation (HSCT) is associated with significant changes in serum UA levels in patients with hematological disorders.
METHODS
Patients who underwent HSCT at our institution between 2001 and 2012 were retrospectively enrolled. Serum UA levels at 3 months before, 1 week before, and 3 months and 1 year after HSCT were examined.
RESULTS
Complete clinical and laboratory information including data regarding UA levels was available for 93 patients. At baseline, the mean UA level was 4.9±2.1 mg/dL, with an overall prevalence of hyperuricemia of 15% (defined as serum UA>6.8 mg/dL). Mean UA levels tended to be higher in patients with acute myeloid leukemia (4.8±2.0 mg/dL) and non-Hodgkin lymphoma (5.1±2.3 mg/dL) and lower in patients with aplastic anemia (mean, 4.2±1.8 mg/dL). UA levels dropped during myeloablative conditioning, reaching a nadir on the day of HSCT (3.27±1.4 mg/dL). Over the 3 months following HSCT, UA levels rose sharply (5.0±2.1 mg/dL) and remained stable up to 1 year after HSCT (5.5±1.6 mg/dL). UA levels in HSCT recipients at 12 months correlated with those of their respective graft donors (Pearson r=0.406, P=0.001).
CONCLUSION
HSCT is associated with significant changes in uric acid levels in patients with hematologic disorders.

Keyword

Uric acid; Hematopoietic stem cell transplantation; Bone marrow

MeSH Terms

Anemia, Aplastic
Bone Marrow
Cohort Studies*
Hematopoietic Stem Cell Transplantation
Hematopoietic System
Humans
Hyperuricemia
Leukemia, Myeloid, Acute
Lymphoma, Non-Hodgkin
Prevalence
Retrospective Studies*
Stem Cell Transplantation*
Stem Cells*
Tissue Donors
Transplants
Uric Acid*
Uric Acid

Figure

• 

  Fig. 1 Patient flow.Abbreviations: UA, uric acid; HSCT, hematopoietic stem cell transplantation.

• 

  Fig. 2 Changes in serum uric acid levels over time after hematopoietic stem cell transplantation. (A) Baseline serum UA levels in patients according to their underlying hematologic diseases. (B) UA levels before and after HSCT. (C) Changes in UA levels over time. Patients were grouped into quartiles based on their baseline serum UA levels in ascending order. Abbreviations: HSCT, hematopoietic stem cell transplantation; UA, uricAbbreviations: HSCT, hematopoietic stem cell transplantation; UA, uric acid; Q, quartile; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; MF, myelofibrosis; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PNH, paroxysmal nocturnal hemoglobinuria; SAA, severe aplastic anemia; GS, granulocytic sarcoma.

• 

  Fig. 3 Correlation of post-transplant uric acid (UA) levels between HSCT recipients and respective donors. UA levels in 89 patients at 12 months after HSCT were correlated with levels of their corresponding graft donors. Correlations were compared using Pearson's coefficient.Abbreviation: HSCT, hematopoietic stem cell transplantation.

Reference

1. Hediger MA, Johnson RJ, Miyazaki H, Endou H. Molecular physiology of urate transport. Physiology (Bethesda). 2005; 20:125–133. PMID: 15772301.

2. Kamble RT, Guo S, Ramos CA, Carrum G. Acute gout at engraftment following hematopoietic transplantation. Am J Hematol. 2011; 86:961–962. PMID: 21948346.

3. Yamauchi T, Negoro E, Lee S, et al. A high serum uric acid level is associated with poor prognosis in patients with acute myeloid leukemia. Anticancer Res. 2013; 33:3947–3951. PMID: 24023333.

4. Carpenter PA, Ziegler JB, Vowels MR. Late diagnosis and correction of purine nucleoside phosphorylase deficiency with allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996; 17:121–124. PMID: 8673045.

5. Zegers BJ, Stoop JW, Staal GE, Wadman SK. An approach to the restoration of T cell function in a purine nucleoside phosphorylase deficient patient. Ciba Found Symp. 1978; 68:231–253. PMID: 115663.

6. Cannell PK, Herrmann RP. Urate metabolism during bone marrow transplantation. Bone Marrow Transplant. 1992; 10:337–339. PMID: 1422489.

7. Rieselbach RE, Bentzel CJ, Cotlove E, Frei E 3rd, Freireich EJ. Uric acid excretion and renal function in the acute hyperuricemia of leukemia. Pathogenesis and therapy of uric acid nephropathy. Am J Med. 1964; 37:872–883. PMID: 14246089.

8. Shulman H, Striker G, Deeg HJ, Kennedy M, Storb R, Thomas ED. Nephrotoxicity of cyclosporin A after allogeneic marrow transplantation: glomerular thromboses and tubular injury. N Engl J Med. 1981; 305:1392–1395. PMID: 7029278.

9. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. N Engl J Med. 1989; 321:287–292. PMID: 2664517.

10. da Silva JB, de Melo Lima MH, Secoli SR. Influence of cyclosporine on the occurrence of nephrotoxicity after allogeneic hematopoietic stem cell transplantation: a systematic review. Rev Bras Hematol Hemoter. 2014; 36:363–368. PMID: 25305170.